5

DEATHVERSE: LET IT DIE Launches on PlayStation Today

Retrieved on: 
Wednesday, September 28, 2022

GungHo Online Entertainment and SUPERTRICK GAMES today launched DEATHVERSE: LET IT DIE on PlayStation 5 and PlayStation 4.

Key Points: 
  • GungHo Online Entertainment and SUPERTRICK GAMES today launched DEATHVERSE: LET IT DIE on PlayStation 5 and PlayStation 4.
  • This free-to-play, multiplayer action game is a spiritual spinoff to LET IT DIE and can be downloaded from the PlayStation Store .
  • DEATHVERSE: LET IT DIE will launch on PC next Wednesday, October 5, and can be wishlisted on Steam here .
  • In DEATHVERSE: LET IT DIE, players compete in a 16-player survival battle arena as contestants of the world-renowned television program DEATH JAMBOREE.

Fierce Whiskers Launches World's First Carbon-Negative Bourbon

Retrieved on: 
Friday, September 23, 2022

AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter, a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas. Five O'Clock Shadow, a single-barrel bourbon release dropping exclusively at the company's first-anniversary event on September 24, 2022, also represents the first bourbon release for this grain-to-grass distillery.

Key Points: 
  • CarbonBetter today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter , a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • "At Fierce Whiskers, we are singularly focused on making the best possible whiskey in Austin, Texas.
  • The work to measure, reduce, and report on Fierce Whiskers' impacts set the stage to release a carbon-negative bourbon by leveraging carbon intensity calculations.

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

Retrieved on: 
Tuesday, September 20, 2022

Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and help protect against high and low glucose levels 1.

Key Points: 
  • Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and help protect against high and low glucose levels 1.
  • The system then increases, decreases, or pauses insulin delivery based on the users desired and customized glucose target.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • Insulets latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections and zero fingersticks3.

Embark on a Brand-New Journey in OCTOPATH TRAVELER II, Launching February 24, 2023

Retrieved on: 
Tuesday, September 13, 2022

Watch the OCTOPATH TRAVELER II announcement trailer here: https://youtu.be/XMpWElRyoxg .

Key Points: 
  • Watch the OCTOPATH TRAVELER II announcement trailer here: https://youtu.be/XMpWElRyoxg .
  • In OCTOPATH TRAVELER II, players will embark on an exciting journey through the brand-new world of Solistia.
  • Path Actions Players can interact with NPCs throughout the world in various ways by using actions unique to each character.
  • OCTOPATH TRAVELER II will be available to pre-order within the next 24 hours** in a Standard Digital Edition for PS5, PS4 and PC via STEAM.

Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer

Retrieved on: 
Monday, September 12, 2022

Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.

Key Points: 
  • Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220912005015/en/
    "We are delighted to welcome Arvind to Spotlights leadership team.
  • "Arvind has deep experience in biologics and will play a key role in helping Spotlight bring a new class of CRISPR ribonucleoprotein therapeutics to patients.
  • Established in 2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies.

NBA® 2K23 Celebrates the Intersection of Music and Basketball Culture with All-New MyCAREER Experience and J. Cole GameStop Exclusive DREAMER Edition Cover for PS5 and Xbox X|S

Retrieved on: 
Thursday, September 1, 2022

* (Photo: Business Wire)

Key Points: 
  • * (Photo: Business Wire)
    J. Cole was also revealed as the cover star for the NBA 2K23 DREAMER Edition dropping this fall for PlayStation 5 and Xbox Series X|S.
  • Exclusively available at GameStop in the U.S. and Canada, the NBA 2K23 DREAMER Edition adds to J. Coles already standout accomplishments as a Grammy Award winning multi-platinum hip-hop artist and certified baller.
  • At the top of that list of talent is our first cover star who truly sits at the intersection of basketball and music.
  • *The Next Gen MyCAREER experience is only available on the new-generation version of NBA 2K23 for PlayStation 5 or Xbox Series X|S.

Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Retrieved on: 
Monday, August 22, 2022

Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022.

Key Points: 
  • Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022.
  • Omnipod 5 has allowed our family to think less about diabetes, said Kara Hornbuckle, an Omnipod 5 user with two children also using the system.
  • in Diabetes Care 4,Omnipod 5 significantly improved time in range, and reduced HbA1c and time in hypoglycemia (
  • Omnipod, Omnipod 5, and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions.

Insulin Patch Pumps Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022

The "Insulin Patch Pumps Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Insulin Patch Pumps Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The insulin patch pumps market research report is one of a series of new reports that provides insulin patch pumps market statistics, including insulin patch pumps industry global market size, regional shares, competitors with a insulin patch pumps market share, detailed insulin patch pumps market segments, market trends and opportunities, and any further data you may need to thrive in the insulin patch pumps industry.
  • Insulin patch pumps help in the convenient delivery of insulin directly into the body and many people with diabetes find insulin pumps to be more convenient than insulin injections.
  • Integration of the advanced technologies in insulin patch pumps is the key trend gaining popularity in the insulin patch pumps market.

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported business highlights and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Continued to execute U.S. launch of PYRUKYND, generating $3.1 million in U.S. net revenue for the second quarter of 2022, the first full quarter following FDA approval.
  • Research and Development (R&D) Expenses: R&D expenses were$74.5 million for the second quarter of 2022 compared to$62.0 millionfor the second quarter of 2021.
  • Selling, General and Administrative (SG&A) Expenses: SG&A expenses were$28.3 millionfor the second quarter of 2022 compared to$29.2 millionfor the second quarter of 2021.
  • Agios will host a conference call and live webcast with slides today at8:00 a.m. ETto discuss second quarter 2022 financial results and recent business activities.

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System

Retrieved on: 
Monday, August 1, 2022

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced its Omnipod 5 Automated Insulin Delivery (AID) System (Omnipod 5) is now fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced its Omnipod 5 Automated Insulin Delivery (AID) System (Omnipod 5) is now fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • Insulets latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks3, and is fully controlled by a compatible personal smartphone.
  • Omnipod, Omnipod DASH, and Omnipod 5 are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions.